Genmab stock

GMAB · Nasdaq Copenhagen · DKK

Compare Genmab
kr 3,529.00Change from previous close: +2.35%Absolute change: +kr 81.00

Close · November 16, 2026

Price history

+80.66% over the period

1 year: from kr 1,975.50 (November 17, 2025) to kr 3,569.00 (November 16, 2026), +80.66%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026kr 3,569.00
October 30, 2026kr 3,912.00
September 30, 2026kr 2,343.00
August 31, 2026kr 2,122.00
July 31, 2026kr 1,858.50
June 30, 2026kr 1,795.00
May 29, 2026kr 1,704.00
April 30, 2026kr 1,690.00
March 31, 2026kr 1,713.00
February 27, 2026kr 1,848.50
January 30, 2026kr 2,022.00
December 30, 2025kr 2,027.00
November 28, 2025kr 2,039.00
November 17, 2025kr 1,975.50

At a glance

  • The company

    Develops antibody-based products for treating cancer and other diseases, with marketed therapies for lymphomas, cervical cancer and multiple myeloma, plus an extensive pipeline

  • Latest results

    Quarter to September 30, 2026 · EPS $37.53 (estimate $22.99)

TickerLandia's take on Genmab

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk lowkr 1,512.00
52-wk highkr 3,947.00

−10.59% from the 52-week high

Analysts · 16 analysts

Average targetkr 4,056.77+14.96% vs. price

Buy 14 · Hold 2 · Sell 0 · Strong buy

TickerLandia Fingerprint: Genmab

Compared with similar companies: very strong momentum, very high earnings stability, and very high risk.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Genmab is pricier than similar companies

Genmab's P/E (trailing 12 months): 47.0, +16% against the median of a group of 10 similar companies (40.4).

Compared with 10 similar companies

Genmab's metrics compared with similar companies
MetricGenmabPosition in the groupBand
P/E (trailing 12 months)47.0Middle
Forward P/E30.2Middle
Operating margin30.6%Middle
ROE12.1%Middle
Debt/equity0.82High

Grey band: the middle half of the group; tick: the median; dot: Genmab. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$1.19B

Latest quarter · Q3 2026

Net income

$342M

Latest quarter · Q3 2026

Quarterly net margin

28.8%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
kr 217.84B
P/E
47.0
EPS
kr 75.25
Volume
20.01K
Daily trading
€111.03M
Dividend yield
0.00%

How Genmab is changing

All results
  • Revenue grew 17.5% a year on average over the last 5 years

  • Operating margin fell from 43.2% to 33.6%

  • Profits turn into cash: free cash flow equal to 120% of net income

Returns

Genmab returns

kr 1,000 invested in Genmab 5 years ago, on November 16, 2021, would be worth kr 1,316 today: +31.55% in total, +5.64% per year. This is the price return only: dividends are excluded.

PeriodGenmabkr 1,000 becomes
1 month+42.65%kr 1,426
6 months+109.56%kr 2,096
Year to date+76.07%kr 1,761
1 year+80.66%kr 1,807
3 years+62.52%kr 1,625
5 years+31.55%kr 1,316
10 years+190.40%kr 2,904

Price only, without dividends. Calculate your investment

The chart in detail

Genmab: technical analysis

Genmab is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 9.8% below its all-time closing high (kr 3,912.00, October 30, 2026).

Trend
Upward
RSI (14 sessions)
62
Between 30 and 70
vs 200-session average
+71.67%

Support and resistance

Price areas where Genmab has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last pricekr 3,529.00
  3. Supportkr 2,216.80−37.18%5 touches, last on October 2, 2026
  4. Supportkr 2,081.00−41.03%3 touches, last on September 11, 2026
  5. Supportkr 1,942.44−44.96%8 touches, last on July 28, 2026

Volatility and risk

Volatility (60 sessions, annualised)
65.8%
Largest fall in the last year
−32.30%

Close of November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Genmab: seasonality

Average monthly price change over 26 years

+6.9%Jan−0.6%Feb+0.4%Mar+2.6%Apr+3.5%May−1.9%Jun+6.6%Jul+0.3%Aug−1.2%Sep+3.4%Oct−0.2%Nov+3.9%Dec

Over the last 26 years, the strongest month for Genmab has been January: +6.90% on average, positive in 15 years out of 26. The weakest has been June: −1.90% on average, positive in 11 years out of 26. November, the current month, has been positive in 12 years out of 26 (−0.18% on average).

Show chart data
MonthAverageMedianPositive years
January+6.90%+4.36%15 of 26
February−0.58%−1.35%10 of 26
March+0.41%+0.41%13 of 26
April+2.61%+2.40%16 of 26
May+3.46%−0.38%12 of 26
June−1.90%−3.45%11 of 26
July+6.56%+4.99%17 of 26
August+0.26%−0.31%13 of 26
September−1.23%−0.97%13 of 26
October+3.39%+2.00%14 of 26
November−0.18%−0.85%12 of 26
December+3.94%+1.63%14 of 26

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Genmab and its competitors

Founded in 1998 and based in Copenhagen, Denmark, Genmab works on antibody-based medicines for cancer and other diseases. Its marketed products include EPKINLY and TEPKINLY for relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma, Tivdak for recurrent or metastatic cervical cancer, and DARZALEX and DARZALEX FASPRO for multiple myeloma, and it has collaboration agreements with companies including AbbVie, Pfizer and Johnson & Johnson.

Headquarters
Copenhagen, Denmark
Employees
3,244
Founded
1998
Chief executive
Jan G.J. de Winkel
Genmab and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
GenmabGMAB$32.21B30.6%47.0+109.56%
UCBUCB$62.44B29.5%26.2+24.51%
Financière de TubizeTUB$11.2B-42,153.6%102.5+21.43%
ALK-AbellóALK.B$8.14B26.9%40.7+0.16%
ABIVAXABVX$7.65B-6,270.4%—−22.36%
Bachem HoldingBANB$7.43B21.8%41.9+5.24%

Same industry or related industries, similar size. Compare Genmab with its competitors · Full profile